Everand Logo

Welcome to Everand!

  • STAT

    Elon Musk wants to test brain-reading implants in paralyzed patients next year

    Elon Musk's startup Neuralink wants to start testing its “brain-machine interface” technology in paralyzed patients by the end of the next year. It has yet to convince the FDA to…
    by Rebecca Robbins Jul 17, 2019 5 minutes
    Source: FREDERIC J. BROWN/AFP/Getty Images

    SAN FRANCISCO — In front of a crowd of techies packed into a planetarium, Elon Musk strode out on stage, waxed philosophical about achieving symbiosis with artificial intelligence, and made his latest ambitious pronouncement in a career that’s been full of them: His startup Neuralink has developed technology meant to be implanted into the brain that’s designed to allow people to operate computers and smartphones with their thoughts.

    With some early animal testing under its belt, Neuralink wants to start human testing of its so-called “brain-machine interface” in paralyzed patients by the end of next year. Notably, the startup has yet to convince the Food and Drug Administration to allow it do so, said Musk, who has tangled with regulators over his other companies Tesla, SpaceX, and the Boring Company. 

    And down the line? Musk wants

    You’re reading a preview, subscribe to read more.

    More from STAT

    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About FDA Dithering On Pharma Patents, WHO Pandemic Talks, And More
    When it comes to a crucial controversy over patents for drug-and-device combination products, the FDA has been MIA.
    STAT1 min read
    STAT+: Element Biosciences, An Illumina Rival, On Its Genomics Ambitions — And Why It Hasn’t Gone Public
    Element Biosciences' modest growth comes at a time when some other players are struggling in a sequencer market dominated by Illumina.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About A Boy Dying In Pfizer Trial; AstraZeneca Yanking Covid Shot, And More
    A young boy died in a clinical trial for an experimental Pfizer gene therapy for Duchenne muscular dystrophy, about a year after receiving the therapy.

    Related Books & Audiobooks